How a Swiss Pharma Company Structured a Milestone-Based Royalty License in China: Technology Licensing Case Study

Executive Summary

In 2021, a mid-sized Swiss biopharmaceutical company headquartered in Basel, Switzerland, entered into a comprehensive technology licensing agreement with a Shanghai-based Chinese pharmaceutical company for the development and commercialization of a novel oncology drug candidate in China. The Swiss company, referred to here as Helvetia BioPharma AG, had discovered a first-in-class small molecule inhibitor targeting a specific protein-protein interaction involved in treatment-resistant breast cancer. Preclinical data demonstrated that the compound, designated HBP-117, achieved tumor regression in 82 percent of xenograft models resistant to existing hormone therapies, representing a potential breakthrough for patients with advanced disease who had exhausted standard treatment options.

This case study examines how Helvetia structured a milestone-based royalty licensing agreement that aligned incentives between the licensor and licensee across the drug development, regulatory approval, and commercialization lifecycle. The transaction was notable for its sophisticated milestone payment structure, which tied financial consideration to specific technical, regulatory, and commercial achievements, and for its careful navigation of China’s pharmaceutical regulatory environment, including the Center for Drug Evaluation (CDE) requirements, the National Medical Products Administration (NMPA) approval processes, and the Patent Linkage and Early Resolution mechanisms introduced under the Fourth Amendment to China’s Patent Law.

The total potential value of the licensing agreement was approximately USD 265 million, comprising upfront payments, development milestones, regulatory milestones, sales milestones, and tiered royalties. At the time of this case study, the agreement had been in effect for approximately three years and had achieved four of the eight milestone events specified in the contract.

Strategic Rationale and Partner Selection

Helvetia’s Motivations for the Chinese Partnership

Helvetia BioPharma was a specialty pharmaceutical company with approximately 380 employees and annual revenues of approximately EUR 120 million, focused exclusively on oncology therapeutics. The company had successfully advanced two drug candidates to Phase II clinical trials in Europe but had no presence in the Chinese pharmaceutical market. Establishing a wholly foreign-owned enterprise to conduct clinical development and regulatory submissions in China would have required a projected investment of approximately EUR 35 million over five years, with significant uncertainty regarding the speed of NMPA review and the potential for regulatory divergence from European Medicines Agency (EMA) standards.

The Chinese partner, referred to here as SinoPharm Oncology Ltd., was a publicly traded biopharmaceutical company listed on the Hong Kong Stock Exchange with an established oncology clinical development infrastructure and a dedicated regulatory affairs team experienced with NMPA submissions. SinoPharm had successfully obtained NMPA approval for two oncology products within the previous five years and maintained relationships with over 40 clinical trial sites across China. The company’s existing commercial infrastructure could support the launch of a new oncology product without requiring significant additional investment in sales and distribution capabilities.

Partner Diligence and Capability Assessment

Helvetia conducted a structured due diligence process over a period of five months, evaluating four potential Chinese partners before selecting SinoPharm. The evaluation criteria included scientific and technical capability (prior experience with small molecule oncology drug development, biomarker identification, and precision medicine approaches), regulatory track record (history of NMPA interactions, CDE meeting success rates, and time from submission to approval for prior products), clinical development infrastructure (number of qualified clinical trial sites, investigator relationships, and patient recruitment capabilities), and commercial readiness (sales force size, hospital access network, and reimbursement expertise).

Helvetia’s due diligence team also conducted a thorough assessment of SinoPharm’s intellectual property management practices, including its systems for maintaining confidentiality of know-how, managing freedom-to-operate analyses, and handling potential patent infringements. This assessment was critical because the licensing agreement would require Helvetia to disclose substantial proprietary know-how, including synthesis processes, formulation methods, and biomarker assay protocols, that was not adequately protected by patents alone.

Milestone Structure and Value Allocation

Upfront Payment and Early-Stage Milestones

The agreement was structured around a series of milestone payments designed to reflect the increasing value of the licensed technology as development progressed and key risks were retired. The upfront technology access fee was set at USD 8 million, payable within 30 days of contract execution. This payment compensated Helvetia for the initial transfer of technical documentation, including the chemical synthesis process, preclinical pharmacology data, initial formulation development results, and the biomarker hypothesis supporting patient selection for clinical trials.

The development milestone phase comprised three payments triggered by achievements in the clinical development program. A USD 5 million milestone was payable upon completion of the first patient dosing in a Phase I clinical trial in China, which required Helvetia to provide clinical trial application (CTA) dossier preparation support and technology transfer for the manufacturing of clinical trial supplies. A USD 12 million milestone was payable upon completion of the Phase I dose-escalation study with demonstration of an acceptable safety profile and identification of the recommended Phase II dose. A USD 20 million milestone was payable upon completion of the first patient dosing in the pivotal Phase II/III registration trial, which represented the point at which the probability of technical success was estimated to have increased from approximately 15 percent to approximately 45 percent based on SinoPharm’s internal risk assessment methodology.

Regulatory Milestones and the NMPA Pathway

A significant innovation in the milestone structure was the inclusion of regulatory milestones specifically tied to China’s pharmaceutical regulatory processes, which differ from those in Europe and the United States in important respects. The NDA submission milestone required the submission of a complete New Drug Application dossier to the NMPA that included both Chinese clinical trial data and, where applicable, data bridging analysis connecting the Chinese trial results to Helvetia’s global clinical development program. The NMPA approval milestone required the issuance of a Drug Registration Certificate by the NMPA for the specific indication being developed.

The agreement also included a regulatory flexibility provision allowing Helvetia to propose alternative regulatory milestones if the NMPA’s regulatory pathway changed during the license term. This provision proved valuable when the CDE introduced new guidance on cancer clinical trial design in 2023 that affected the statistical analysis plan for the pivotal trial. The parties agreed to modify the clinical endpoint definition for the Phase II/III trial to align with the updated CDE guidance, and the new regulatory milestone was restated to reflect the revised trial design without requiring renegotiation of the payment amounts.

Royalty Structure and Financial Mechanics

Tiered Royalty Rates

The royalty structure employed a tiered approach that provided Helvetia with increasing returns as SinoPharm’s commercial success grew, while maintaining the licensee’s incentive to maximize sales. Royalties were calculated on annual net sales of HBP-117 in China, with rates structured as follows: net sales below USD 50 million per year attracted a royalty rate of 8 percent; net sales between USD 50 million and USD 150 million attracted a rate of 12 percent; net sales between USD 150 million and USD 350 million attracted a rate of 15 percent; and net sales exceeding USD 350 million attracted a rate of 18 percent. The tiered structure was designed to reflect the increasing profitability of the product as fixed costs of manufacturing and distribution were covered by higher sales volumes.

The agreement included a standard royalty stacking provision that reduced the royalty rate proportionally if SinoPharm was required to pay royalties to third parties for patents or technology necessary for the commercialization of HBP-117. The stacking cap was set at 50 percent of the applicable royalty rate, meaning that the royalty payable to Helvetia could not be reduced by more than half due to third-party royalty obligations. This provision protected Helvetia’s minimum return while allowing SinoPharm to in-license additional complementary technologies that might enhance the product’s commercial potential.

Patent Term and Royalty Duration

The royalty obligation was structured to continue until the later of (a) the expiration of the last-to-expire valid patent claim within the licensed patent portfolio covering HBP-117 in China, or (b) twelve years from the date of first commercial sale of the product in China. The 12-year royalty term, which extended beyond the standard patent term for pharmaceutical products in China (20 years from filing date, potentially extendable by up to five years through patent term extension for regulatory review delays), reflected the value of the underlying know-how and regulatory data that would support the product even after patent expiration.

China’s introduction of a patent term extension mechanism for pharmaceutical products under the Fourth Amendment to the Patent Law, effective June 1, 2021, was a significant factor in the parties’ negotiation of the royalty duration. The possibility of obtaining up to five years of additional patent term for regulatory review delays could extend the patent protection period for HBP-117 to approximately 25 years from the original patent filing date, potentially adding significant value to the royalty stream. The agreement included a provision requiring SinoPharm to cooperate with Helvetia in applying for patent term extension for any applicable licensed patents in China.

IP Protection and Regulatory Exclusivity

Patent Linkage and Early Resolution Mechanisms

The Fourth Amendment to China’s Patent Law, along with the associated Implementing Regulations and the Patent Adjudication Guidelines issued by the CNIPA, established a patent linkage system and early resolution mechanism for pharmaceutical patents, modeled in part on the Hatch-Waxman framework in the United States. Under this system, generic drug applicants must notify patent holders of their applications and either certify that their product does not infringe valid patents or challenge the validity of the relevant patents. Helvetia’s licensing agreement included provisions requiring SinoPharm to enforce the licensed patents against generic challengers and to share the costs and benefits of any patent litigation with Helvetia on a 50:50 basis.

This patent linkage framework added a new dimension to the IP protection strategy for licensed pharmaceutical products in China. Under the previous regulatory system, SinoPharm would have had limited visibility into generic entry threats until a generic product actually appeared on the market. The patent linkage system provides an early warning mechanism that allows the patent holder to initiate infringement proceedings or patent validity challenges at the generic application stage, potentially preventing market entry before significant commercial damage occurs.

Data Exclusivity and Regulatory Protection

In addition to patent protection, the licensing agreement addressed China’s regulatory data protection framework. Under China’s Measures for the Protection of Drug Testing Data (implementing the data exclusivity provisions of the Implementing Regulations of the Drug Administration Law), innovative drugs receive a six-year data exclusivity period from the date of NMPA approval. During this period, the NMPA is prohibited from relying on the innovator’s clinical trial data to approve generic versions of the same drug without the innovator’s authorization. Helvetia’s agreement required SinoPharm to assert data exclusivity rights in all NMPA submissions and to notify Helvetia if any third party attempted to rely on the data.

The interaction between data exclusivity and patent protection was an important consideration in the financial modeling of the licensing agreement. In a scenario where HBP-117 obtained NMPA approval in 2026 with five years of patent term extension, the data exclusivity period would expire in 2032 while patent protection would extend to approximately 2038. The royalty stacking provision and the 12-year minimum royalty term were designed to ensure that Helvetia received adequate compensation during the period after data exclusivity expiration but before patent expiration, when generic entry risk remained low but the data-exclusivity barrier to competition would no longer apply.

Implementation Progress and Challenges

Clinical Development Timeline

As of the time of this case study, SinoPharm had achieved four of the eight milestone events. The upfront payment was made within the contracted 30-day period. The Phase I CTA was submitted to the CDE in March 2022, and approval was received in August 2022, representing a review period of approximately five months, which was consistent with the standard 60-120 working day review timeline for innovative drug CTAs in China. The first patient was dosed in October 2022, triggering the USD 5 million development milestone. The Phase I study was completed in March 2024 with 48 patients enrolled across six clinical trial sites, demonstrating an acceptable safety profile and establishing the recommended Phase II dose of 400 mg once daily.

The fourth milestone, first patient dosing in the pivotal Phase II/III registration trial, was achieved in September 2024, approximately three months later than the initial projections. The delay was primarily attributed to the need to amend the clinical trial protocol to incorporate the updated CDE guidance on oncology trial endpoints, which required additional consultation with the CDE and a resubmission of the amended protocol. The protocol amendment process added approximately 12 weeks to the trial start timeline but was essential to ensure that the trial design met the NMPA’s current regulatory standards for registration trials.

Financial Performance and Value Realization

Helvetia received total milestone payments of USD 45 million over the first three years of the agreement (USD 8 million upfront, USD 5 million for first patient dosing, USD 12 million for Phase I completion, and USD 20 million for pivotal trial initiation). This represented approximately 17 percent of the total potential milestone value of USD 265 million. Helvetia’s investment in the Chinese regulatory and clinical development support, including personnel costs for two dedicated regulatory affairs professionals and one clinical operations manager based in Shanghai, totaled approximately USD 1.8 million over the same period, resulting in a net return of approximately USD 43.2 million from the milestone payments alone.

Lessons for Foreign Biopharma Technology Licensors

Helvetia’s experience offers several important lessons for foreign pharmaceutical and biotechnology companies considering technology licensing agreements in China. First, the milestone structure must be carefully calibrated to the realities of China’s regulatory environment. Standard milestone definitions developed for US or European licensing agreements, which typically assume a linear development pathway through IND, Phase I, Phase II, Phase III, and NDA/BLA submission, may not align well with China’s regulatory processes, which include unique requirements such as the CDE communication meeting system, the clinical trial notification system (which replaced the former clinical trial approval system for certain applications), and the priority review and conditional approval pathways available for innovative drugs addressing unmet medical needs.

Second, the patent linkage system introduced under the Fourth Amendment to China’s Patent Law adds a new dimension to IP protection strategy that foreign licensors should incorporate into their licensing agreements. The ability to prevent generic market entry through early resolution mechanisms can significantly extend the commercial value of licensed pharmaceutical products in China, but the effectiveness of these mechanisms depends on the quality of the patent claims and the willingness of the licensee to enforce them. Foreign licensors should consider including provisions that require the licensee to petition the CNIPA for patent term extension, to record the patent in the Patent Linkage Registry, and to pursue patent infringement actions against generic challengers under the early resolution mechanism.

Third, the regulatory flexibility provision included in Helvetia’s agreement proved to be one of the most valuable contractual features. China’s pharmaceutical regulatory environment is evolving rapidly, with new guidance documents, technical standards, and regulatory pathways being introduced on an ongoing basis. A licensing agreement that rigidly defines milestones based on a static regulatory framework will inevitably encounter misalignment as regulations change. Including provisions that allow the parties to adjust milestone definitions and timelines in response to regulatory changes, while maintaining the aggregate value of milestone payments, can significantly reduce the risk of disputes and renegotiations over the multi-year development horizon typical of pharmaceutical licensing agreements.

Conclusion

Helvetia BioPharma’s milestone-based technology licensing agreement with SinoPharm Oncology demonstrates a sophisticated approach to structuring pharmaceutical technology transfers in China. The alignment of payment milestones with risk-reduction events, the careful integration of China-specific regulatory requirements into the contractual framework, and the comprehensive IP protection strategy that leveraged both patent linkage mechanisms and data exclusivity protections collectively created a robust licensing structure that has survived its first three years with four of eight milestones successfully achieved. For foreign pharmaceutical companies seeking to access China’s growing innovative drug market, the milestone-based royalty licensing model, adapted to the specific features of China’s regulatory and patent landscape, offers a proven structure that balances risk, reward, and operational complexity.